These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 25189725)

  • 1. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
    Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
    J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
    Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
    Koopmans SM; van Marion AM; Schouten HC
    Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
    Tefferi A
    Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
    Silver RT; Kiladjian JJ; Hasselbalch HC
    Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging treatments for classical myeloproliferative neoplasms.
    Vannucchi AM; Harrison CN
    Blood; 2017 Feb; 129(6):693-703. PubMed ID: 28028027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemic transformation in essential thrombocythemia.
    Bhatt VR
    Future Oncol; 2014 Dec; 10(16):2593-602. PubMed ID: 25531047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double transformation of a hematopoietic malignancy and severe associated thrombopathy. Case presentation and review of the literature.
    Cişleanu D; Onisâi M; Vlădăreanu AM; Găman M; Neagul AM; Bumbea H; Iova A; Baluţa C; Cazaceanu O; Begu M; Ilea A
    Rom J Intern Med; 2011; 49(2):137-44. PubMed ID: 22303605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
    Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.